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Abstract
Background: Multiple myeloma (MM) is a malignant proliferation of plasma B cells. Based on recurrent aneuploidy
such as copy number alterations (CNAs), myeloma is divided into two subtypes with different CNA patterns and
patient survival outcomes. How aneuploidy events arise, and whether they contribute to cancer cell evolution are
actively studied. The large amount of transcriptomic changes resultant of CNAs (dosage effect) pose big challenges
for identifying functional consequences of CNAs in myeloma in terms of specific driver genes and pathways. In this
study, we hypothesize that gene-wise dosage effect varies as a result from complex regulatory networks that
translate the impact of CNAs to gene expression, and studying this variation can provide insights into functional
effects of CNAs.
Results: We propose gene-wise dosage effect score and genome-wide karyotype plot as tools to measure and
visualize concordant copy number and expression changes across cancer samples. We find that dosage effect in
myeloma is widespread yet variable, and it is correlated with gene expression level and CNA frequencies in
different chromosomes. Our analysis suggests that despite the enrichment of differentially expressed genes
between hyperdiploid MM and non-hyperdiploid MM in the trisomy chromosomes, the chromosomal proportion of
dosage sensitive genes is higher in the non-trisomy chromosomes. Dosage-sensitive genes are enriched by genes
with protein translation and localization functions, and dosage resistant genes are enriched by apoptosis genes.
These results point to future studies on differential dosage sensitivity and resistance of pro- and anti-proliferation
pathways and their variation across patients as therapeutic targets and prognosis markers.
Conclusions: Our findings support the hypothesis that recurrent CNAs in myeloma are selected by their functional
consequences. The novel dosage effect score defined in this work will facilitate integration of copy number and
expression data for identifying driver genes in cancer genomics studies. The accompanying R code is available at
http://www.canevolve.org/dosageEffect/.
Keywords: Copy number alteration, Dosage effect, Multiple myeloma, Hyperdiploid, Integrative genomics
Background
Multiple myeloma (MM or myeloma) is a malignant pro-
liferation of plasma B cells that contain prevalent genomic
alterations [1,2]. Based on copy number alterations and
translocations, myeloma is divided into two main sub-
types. The hyperdiploid multiple myeloma (HMM) is
characterized by the trisomy (three copies) of eight
chromosomes, 3, 5, 7, 9, 11, 15, 19 and 21, and the non-
hyperdiploid multiple myeloma (NHMM) is often associ-
ated with chromosome 13 hemizygous deletion and
translocations between the immunoglobulin heavy chain
gene and proto-oncogenes [3]. The copy number alter-
ations (CNAs) in other chromosome regions such as 1q,
6q, 8p, and 16q occur in both subtypes (Figure 1).
Excessively present in myeloma, CNAs are also fre-
quent genomic alteration events in most hematological
cancers and many solid cancers [4]. How CNAs arise and
whether they contribute to cancer cell evolution is actively
debated [5,6]. Some argue that CNAs are a benign side
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which results in many types of mutations and chromo-
some mis-segregation [7]. Others propose that CNAs have
functional consequences on survival and proliferation of
cancer cells [8,9], and therefore could be subjected to se-
lection during cancer cell evolution. The eight non-
random trisomy chromosomes that characterize HMMs,
and better patient survival rates in HMM than in NHMM
support the functional selection of CNAs in myeloma
[10]. More substantial analysis is needed to identify candi-
date driver genes or pathways affected by CNAs and de-
sign experiments that interfere with these candidates to
study their functional effects on cancer cells. However,
thousands of genes located in the CNA regions in mye-
loma have altered mRNA expression levels directly in-
duced by copy number changes, a phenomenon termed
Figure 1 SNP copy number-based clustering provides an overall view of myeloma genomic heterogeneity and subtypes. Myeloma
samples in the IFM dataset are clustered based on their SNP-array copy numbers from left to right. SNPs are ordered by chromosome positions
from top to bottom. Blue color indicates copy number loss, white color indicates copy number close to normal, and red color indicates copy
number gains. The horizontal bars on the top indicate samples clusters with copy number features of NHMM (blue) and HMM (red).
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genes with dosage effect, transcription factors and epigen-
etic modifiers could further modulate mRNA expression
of their many downstream genes [12]. These large number
of directly and indirectly affected genes by CNAs pose big
challenges for identifying functional consequences of
CNAs in myeloma in terms of specific driver genes and
pathways, and for studying the interplay between these
driver genes and other genetic mutations during myeloma
cell evolution.
Technological development in genomics has promoted
multi-scale and integrative studies of cancer [13]. In par-
ticular, paired gene expression and copy number profiling
for the same cancer samples has helped identifying driver
cancer genes in CNA regions, expression signatures that
correlate with particular CNAs, and new cancer subtypes
[4,14-16]. Copy number dosage effect has been a direct
or implied question in such studies, which have shown
the dosage effect of genes in various cancer types such as
leukemia, lymphoma, liver cancer and breast cancer
[17-20]. In myeloma, Dickens and colleagues have identi-
fied 170 genes with homozygous deletions and corre-
sponding loss of expression using paired gene expression
and copy number alteration profiles [21]. Cell death net-
work is over-represented in these genes, and patients
with these deletions have worse overall survival. Agnelli
and colleagues have compared myeloma samples with
and without chromosome 13 deletions and identified 67
down-regulated genes of which 44 maps to chromosome
13 [22]. These genes are involved in protein biosyn-
thesis, ubiquitination and transcriptional regulation. Many
genes and pathways are differentially expressed between
the HMM and NHMM subtypes, which have distinct
CNA profiles [23,24]. These results support that CNAs
have functional consequences through affecting gene ex-
pression and may contribute to myeloma cell evolution
through cancer-related pathways.
When the extent of CNAs spans multiple chromo-
somes and hundreds or thousands of genes, such as in
myeloma, current dosage effect studies integrating gene
and copy number data have limitations. First, they tend
to identify pathways with broad functions such as prolifer-
ation and apoptosis, whose gene members are enriched in
the genes with dosage effect. Although these pathways
provide insights into possible contribution of CNAs to
cancer, they do not suggest specific therapeutic targets to
improving current treatment regimes. Second, regulatory
feed-back loops and dosage compensation mechanisms
may attenuate the dosage effect of many genes [25], caus-
ing them missed by correlation analysis between copy
number and expression or differential expression analysis
between CNA groups.
Based on these observations, we hypothesize that
gene-wise dosage effect varies as a result from complex
regulatory networks that translate the impact of CNAs to
gene expression, and studying this variation can provide
insights into functional effects of CNAs. We propose a
gene-wise dosage effect score to measure the prevalence
of concordant copy number and expression changes
across the samples in a dataset. Applied to two myeloma
datasets, a genome-wide karyotype plot of the dosage ef-
fect reveals the variation of dosage effect between genes
and across chromosomes. We then study the potential
causes of these variations in terms of gene’s overall expres-
sion level and chromosomes’ CNA frequency. Unexpect-
edly, four non-trisomy chromosomes (13, 14, 16, and 22)
emerge as having the highest proportion of their genes
that are dosage sensitive. Dosage sensitive genes and dos-
age resistant genes are enriched with different functional
pathways. In particular, the apoptosis pathway is enriched
in dosage resistant genes, raising interesting hypothesis
about the mechanism of this phenomenon and its utility
as a prognosis marker. Taken together, our findings sup-
port that recurrent CNAs in myeloma are selected by their
functional consequences. The proposed dosage effect ana-
lysis method will facilitate many genomics studies inte-
grating gene copy number and expression data.
Methods
Microarray datasets
We used two datasets providing paired genome-wide
profiles of copy number alterations and gene expres-
sion for newly diagnosed myeloma patients. The first is
the IFM (Intergroupe Francophone du Myelome) dataset
with 170 patients profiled in our laboratory by high-density
Affymetrix 500 K SNP arrays and Exon ST 1.0 expres-
sion arrays (GEO identifiers GSE12896 and GSE39754).
Patient characteristics and clinical information have been
reported previously [2]. The second is the Dickens dataset
with 71 patients profiled by Affymetrix 500 K SNP ar-
rays and Human Genome U133 Plus 2.0 expression arrays
(GSE15695) [21].
Primary analysis of gene expression and copy
number data
The gene expression and copy number profiling data
were preprocessed with the dChip software [26,27] to
obtain expression and copy number estimates. The gene
expression profiles were quantile-normalized and model-
based signals were computed [26,27]. Gene probe set in-
tensity values were averaged when more than one probe
sets per gene were available. To assess the impact of al-
ternative methods for handling Affymetrix array probe
sets on Dosage effect scores, we also obtained alternative
expression estimates for the IFM dataset from a CDF
(HuEx-1_0-st-v2,coreR3,A20071112,EP.CDF) provided by
Purdom et. al. [28]. This CDF, available form aroma.
affymetrix website, groups Affymetrix “core” probesets into
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probe is uniquely mapped to only one transcript cluster,
allowing for a unique gene expression value for each indi-
vidual gene after pre-processing and eliminating the need
to use avarage value for each gene.
A gene’s copy number was obtained by averaging the
copy numbers of the SNPs within 5 kb of the gene’s
transcription region. Further analysis was done with the
R programming environment. We created gene expres-
sion and copy number data matrices based on unique
gene symbols, and then identified the gene symbols
common between the two data matrices for dosage ef-
fect analysis: 12836 genes for the IFM dataset and 12359
genes for the Dickens dataset.
Hyperdiploidy status
Since there were no published hyperdiploidy data deter-
mined by FISH for both datasets, the myeloma hyper-
diploidy status was defined using the copy number
information from SNP arrays. To determine the threshold
for separating samples in to two subtypes, we plotted the
distribution of the median copy number of the trisomy
chromosomes. We observed a bimodal distribution with
two peaks at 2 and 2.6. The HMM samples have a peak
near 2.6 (and not 3) due to the normalization effect across
arrays. We chose the midway value (2.3) between the two
peaks as the cutoff to call HMM and NHMM samples
from the copy number data. 77 of 170 IFM samples, and
42 of 71 Dickens samples were called as HMM, and the
rest samples were called as NHMM.
Defining dosage effect score (DES)
We defined a gene-wise dosage effect score (DES) to iden-
tify genes whose copy number changes modulate their
own expression. The DES is the ratio between “dosage ef-
fect sample number” and “CNA sample number”.T h e
“CNA sample number” of a gene, is the number of samples
in a dataset that have CNA at the gene (copy number <1.7
or> 2.3, considering signal noise and normal cell contam-
ination). The “dosage effect sample number” o ft h eg e n ei s
defined using two steps. First, using the samples with no
copy number changes at the gene (copy number within 1.7
and 2.3), the mean (normal_mean) and standard deviation
(normal_sd) of the gene expression values is calculated.
Next, we count the total number of samples that have
CNA at this gene and their expression levels at the gene
change more than random in the same direction as their
C N A( i . e .t h es a m p l e sw h o s eg e n ee x p r e s s i o nv a l u ea r e
higher than normal_mean+ normal_sd for amplification
samples or lower than normal_mean – normal_sd for dele-
tion samples). The number of these samples is the “dosage
effect sample number” at the gene.
Being a ratio, DES ranges between 0 and 1. Larger
DES indicates stronger dosage effect at the gene in the
sense that a larger proportion of CNA samples have
concordant expression changes. To ensure reliability,
DES is computed only for genes whose CNA sample
number is greater than 10% of all samples. As an ex-
ample, the gene EIF3K has CNA in 55.88% of samples in
the IFM data set. Utilizing mean +/− 1 SD criteria, the
percent of samples with both copy number alteration and
concordant expression changes are 25.29%. EIF3K has
the DES of 0.45 (.2559/.5588) in the IFM dataset.
Differential and functional enrichment analysis
Differential expression was identified with the LIMMA
Bioconductor package, and Benjamini-Hochberg mul-
tiple hypothesis correction was carried out using the R
package multtest. Differential gene expression was called
at the adjusted p-value <0.05. We used the DAVID web
server for gene function enrichment analysis using gene
ontology (GO) categories (GOTERM_BP_FAT, GOTERM_
CC_FAT and GOTERM_MF_FAT) [29].
Results
Differentially expressed genes between HMM and NHMM
are enriched in the trisomy chromosomes
A primary difference between the HMM and NHMM sub-
types is the presence of three copies (trisomy) of eight spe-
cific chromosomes in HMM and normal copy numbers for
them in NHMM (Figure 1). To check whether the trisomy
chromosomes influence the expression of the genes lo-
cated within them, we compared the HMM and NHMM
samples of the IFM dataset for differentially expressed
genes. The trisomy chromosomes contained more HMM
up-regulated genes than HMM down-regulated genes
(Figure 2). Specifically, 744 of the 4702 (15.8%) tri-
somy chromosome genes are up-regulated in HMM,
while only 416 of the 8134 (5.1%) non-trisomy chromo-
some genes are up-regulated in HMM (Fisher’s exact test
p-value< 2.2e-16).
In contrast, genes down-regulated in HMM are signifi-
cantly depleted from the trisomy chromosomes (140 of
1798 down-regulated genes locate in the trisomy chro-
mosomes, p-value <2.2e-16). Such enrichment is not
due to that expressed genes in myeloma preferentially
locate in the trisomy chromosomes. The reason is as fol-
lows: when the expressed genes in myeloma is defined
as the top 50% genes ranked by median expression level
across the IFM samples, 51.4% (2418 genes) of the tri-
somy chromosome genes are expressed and 49.2% (3999
genes) of the non-trisomy chromosomes are expressed
(p-value =0.014).
Chromosome 1q amplification is observed in ~40% of
myeloma patients (e.g. Figure 1) and many genes on
1q21 have been reported as over-expressed when com-
paring myeloma against normal. In the IFM data, we ob-
serve much more down-regulated genes than up-regulated
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NHMM samples (Figure 2). This can be due to more fre-
q u e n ta m p l i f i c a t i o no fc h r o m o s o m e1 qi nN H M Mt h a ni n
HMM (Figure 1). These results suggest that chromosome
copy number changes in myeloma could have direct effect
on the expression level of a substantial number of genes.
Widespread but variable dosage effect in myeloma
To understand the global and spatial patterns of how
copy number alterations (CNAs) affect gene expression
in myeloma, we integrated paired gene expression and
copy number profiling data from two myeloma datasets.
We defined a dosage effect score (DES) for each gene as
the proportion of CNA samples that have concordant
copy number and gene expression changes (see Methods),
and then visualized the gene-wise CNA frequencies
and DES in a genome-wide karyotype plot (Figures 3A
and 4A). The plots show that the dosage effect in mye-
loma patients is widespread and there is an overall similar
dosage effect patterns between the IFM and Dickens
datasets. The impact of dosage on gene expression can be
observed at most chromosomes, such as the trisomy chro-
mosomes 9, 11 and 15, and chromosomes 13, 14 and 16,
which contain hemizygously deleted regions.
DES ranges between 0 and 1, and summarizes con-
cordant copy number and gene expression changes. A
value close to 0 and 1 indicates weak and strong dosage
effect, respectively. The distribution of DES in the IFM
data shows a large variation of DES across genes: 58%
genes have low dosage effect (DES<0.2, Figure 3B), 37%
have medium dosage effect (DES between 0.2 and 0.4), and
only 5.2% (611 genes) have high dosage effect (DES>0.4).
For the Dickens data the distribution is similar: 64%,
30%, and 5.5% (655) genes have low, medium and high
dosage effect, respectively (Figure 4B). The high dos-
age effect genes from the two datasets have 123 genes
in common (Fisher’s exact p-value <2.2e-16). The top
100 dosage-sensitive as well as resistant-genes for IFM
and Dickens datasets are reported in Additional files 1
and 2. Deletion in chromosome 13 is a prognostic fac-
tor in MM [3]. Therefore genes showing strong dos-
age effect on this chromosome may be important for
MM. A list of dosage sensitive genes on this chromo-
some is available in Additional file 3. ELOVL7, PTDSS1,
POLR1D, TBC1D22A, CCNC and TCF25 are some of the
interesting genes with cancer related functions identified
from the DES analysis. Additional file 4 summarizes cancer
r e l a t e df u n c t i o n sb a s e do nP u b M e df o rt o p5 0d o s a g es e n -
sitive genes in both IFM and Dickens datasets.
Higher gene expression level is associated with stronger
dosage effect
To explain the variation of dosage effect for the genes
with similar CNA frequencies, such as those in the same
trisomy chromosome (Figure 3A), we correlated gene
expression levels with the DES. The motivation is that
some genes are expressed at higher level than others,
and genes that are not expressed in myeloma will not
exhibit any dosage effect. We first ordered all the genes
by their median expression levels across samples and
divided the genes into five equal-size groups (Figure 5,
X-axis), and then compared the proportion of genes
Figure 2 The number of differentially expressed genes between HMM and NHMM by chromosome. Red and blue bars represent
up-regulated genes and down-regulated genes in HMM samples compared to NHMM samples, respectively. No normal samples are available or
used for this dataset. On the X-axis label, trisomy chromosomes in HMM are colored in red.
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groups (Figure 5, Y-axis). We found that for both datasets,
higher expressed gene groups contain significant larger
proportion of genes with high dosage effect (Cochran-
Armitage p-value<2.2e-16 for both datasets).
Higher chromosomal CNA frequency is correlated with
higher proportion of dosage sensitive genes
The proportion of dosage sensitive genes (DES>0.4) in
each chromosome also varies across chromosomes, ran-
ging from about 2% for chromosome 17 to >12% for
chromosome 13 (Figure 6A). These proportions strongly
correlate between the two datasets. Interestingly, the
chromosomal proportion of dosage sensitive genes is
highest for four non-trisomy chromosomes (chromo-
somes 13, 14, 16 and 22) and lower for the trisomy chro-
mosomes (marked red in Figure 6A). In contrast, the
proportion of genes with medium dosage effect in each
chromosome is not correlated between the two datasets
(Figure 6B).
Because the pattern of recurrent chromosomal gains and
losses in myeloma are conserved across different datasets
(Figures 1 and 6C), we asked whether the variation in the
proportion of dosage sensitive genes across chromosomes
is correlated with the myeloma CNA patterns. We com-
pared the proportion of dosage sensitive genes with the
proportion of genes with CNA across chromosomes. For
non-trisomy chromosomes (marked blue in Figure 6D, 6E),
we observed that larger CNA proportions associate with
higher proportion of dosage sensitive genes.
Both dosage sensitive genes and differentially expressed
genes between HMM and NHMM are enriched by protein
translation and localization processes
To explore the functional consequences of dosage effect,
we performed functional enrichment analysis for dosage
Figure 3 The CNA frequency and dosage effect karyotype plot for the IFM dataset. (A) The chromosomes are numbered from 1 to 22 and
marked by gene locations. For each gene, the height of red and blue bars represents the percent of samples with copy number gain and copy
number loss, respectively. The height of gray bars at the beginning of chromosomes indicates 100%. The colors represent the dosage effect score
(DES) of genes, which measures concordant copy number and expression changes. (B) The distribution of gene dosage effect scores.
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and 2 for the IFM and Dickens dataset respectively) using
the DAVID gene ontology Web server. Translation, protein
localization, and proteolysis processes are enriched in dos-
age sensitive genes from the IFM dataset (Additional file 5:
Table S1). Translation, protein localization and mitochon-
drial processes are enriched in dosage sensitive genes from
the Dickens dataset (Additional file 5: Table S2).
Since the distinct CNA patterns in the HMM and
NHMM subtypes can induce subtype specific expression
changes through dosage effect, we asked how dosage ef-
fect analysis compares to differential expression analysis.
We compared 2958 differentially expressed genes be-
tween HMM and NHMM (Figure 2) and 611 dosage
sensitive genes (DES>0.4) from the IFM dataset. Their
overlap of 306 genes is highly significant (Fisher’se x a c t
test p-value< 2.2e-16). Gene ontology groups enriched
in HMM up-regulated genes include translation and
RNA-binding, and those enriched in NHMM up-regulated
genes include protein localization, proteolysis, cell cycle,
RNA processing and histone modification (Additional
file 5: Table S3). These results suggest that differentially
expressed genes between the two myeloma subtypes are
mainly driven by dosage sensitive genes located in distinct
CNA regions of the two subtypes.
Dosage resistant genes are enriched by the apoptosis
process
Compared to dosage sensitive genes, dosage resistant
genes (Additional file 1 and Additional file 2) may be
subjected to more stringent dosage compensatory net-
works such as feedback loops. Dosage resistant genes
were defined as the top 20% of highly expressed genes
(Group 5 from Figure 5) that have DES <0.2 (genes
listed in Additional files 1 and 2). Gene ontology enrich-
ment analysis of dosage resistant genes identified processes
Figure 4 The CNA frequency and dosage effect karyotype plot for the Dickens dataset. (A) The chromosomes are numbered from 1 to 22
and marked by gene locations. For each gene, the height of red and blue bars represents the percent of samples with copy number gain and
copy number loss, respectively. The height of gray bars at the beginning of chromosomes indicates 100%. The colors represent the dosage effect
score (DES) of genes, which measures concordant copy number and expression changes. (B) The distribution of gene dosage effect scores.
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monly enriched in both dosage sensitive and resistant
genes. However, apoptosis emerged as a distinct process
only enriched in dosage resistant genes in both datasets
(Additional file 5: Table S4, Table S5).
Alternative pre-processing of Affymetrix Exon arrays does
not impact dosage effect score substantially
It is valuable to assess impact of alternative methods for
handling Affymetrix Exon array probe sets on DES.
Therefore, we obtained alternative expression estimates
for the IFM dataset from a CDF provided by Purdom
et al. [28]. For the IFM dataset, the Pearson correlation
coefficient for the mean of gene expression estimates
a c r o s st h es a m p l e so fdChip and aroma.affymetrix normal-
ized data is 0.86 (12192 genes; p< 2.2e-16) and the correl-
ation for DES scores is 0.81 (10960 genes; p <2.2e-16).
Moreover, the results from functional enrichment ana-
lysis of DES scores from the IFM dataset derived using
aroma.affymetrix expression estimates overlap signifi-
cantly with those obtained from dChip expression esti-
mates (Additional file 5: Figure S1A and S1B, Additional
file 5: Table S6 and S7). In addition, we can observe simi-
lar DES patterns for chromosomal locations (Figure 3 and
Additional file 5: Figure S2). Please see Additional file 5
for detailed enrichment results. Thus, conclusions from
our analysis are robust against different pre-processing
methods.
Discussion
Cancer genomes such as those of multiple myeloma har-
bor many types of genomic aberrations. Among them,
CNAs of entire chromosomes or focal chromosomal re-
gions have been extensively detected from many cancer
Figure 5 The correlation between dosage effect and gene expression level. (A) The IFM dataset, and (B) the Dickens dataset. Group 1
includes the 20% genes that have lowest overall expression across samples, and Group 5 includes the 20% genes that have highest
overall expression.
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sively parallel sequencing technologies. Paired copy num-
ber and gene expression profiling of the same cancer
samples has enabled integrative analysis identifying driver
oncogenes, improving classification of cancer subtypes,
and provided better understanding of molecular pathways
dysregulated in cancer [4,15,19,30]. In myeloma genomes,
prevalent and recurrent patterns of 8 trisomy chromo-
somes and deletions of specific chromosomes (1p, 6q, 8p,
13, 16q; see Figure 1) provide a model system to study the
effect of CNAs on gene expression. Although previous
studies hinted at the copy number dosage effect in various
cancer types including myeloma [11,18], in this study we
have for the first time defined dosage effect score,
highlighted its variation across genes and chromosomes,
and studied the potential consequence of these variations
in terms of dosage sensitive genes and dosage-resistant
genes. Other genomic changes such as copy-neutral loss of
heterozygosity can be inferred from SNP array data, and
they could affect gene expression levels. Study of these al-
terations can be followed up in the future.
Defining a gene-wise dosage effect score (DES) allows
us to compare and visualize the impact of CNAs on gene
expression at the level of individual genes, across the
genome and between datasets. The DES score was calcu-
lated only for those genes that have copy number alter-
ations in at least 10% of patients and vary their expression
beyond the mean expression +/− one SD, as a safeguard in
the process. Because cis-regulatory factors may reduce the
gene expression output even if the copy number has in-
creased, using higher SD values could result in significantly
higher amount of false negatives. In practice, users of our
method can use any suitable threshold of choice. The
visualization of distribution of DES along chromosomes
suggests that dosage effect in myeloma is widespread and
variable across the genome (Figures 3 and 4). Most genes
Figure 6 The correlation between dosage sensitive genes and CNA frequency across chromosomes. (A) The proportion of genes in each
chromosome that are dosage sensitive (DES>0.4). X-axis: the IFM dataset, Y-axis: the Dickens dataset. (B) The proportion of genes in each
chromosome that have medium dosage effect (0.2<= DES<= 0.4). X-axis: the IFM dataset, Y-axis: the Dickens dataset. (C) Copy number
alteration frequency in each chromosome compared between the two datasets. Each point represents the CNA (copy number <1.7 or>2.3)
frequency of a gene across samples, averaged over all the genes in a chromosome. (D, E) The proportion of dosage sensitive genes (Y-axis) is
plotted against the average CNA frequency (X-axis) for different chromosomes, for the IFM data (D) and the Dickens data (E).
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genes are highly dosage sensitive. We analyze two contrib-
uting causes for such variation: highly expressed genes are
more likely to have higher dosage effect (Figure 5), and
higher frequency of CNAs in a chromosome correlates
with higher proportion of dosage sensitive genes (Figure 6D
and 6E). Interestingly, although three non-trisomy chro-
mosomes (14, 16, 22) have lower frequency of CNAs than
the 8 trisomy chromosomes, the proportion of dosage sen-
sitive genes in these non-trisomy chromosomes are higher
than in the trisomy chromosomes (Figure 6D and 6E). This
could be due to that 3-copy gains in trisomy chromosomes
lead to 1.5 fold expression changes, while 1-copy losses
in non-trisomy chromosomes lead to 2 fold expression
changes. The larger relative impact on gene expression
of copy number losses may lead to higher proportion of
dosage sensitive genes in non-trisomy chromosomes.
Dosage sensitive genes are enriched by genes with
function in protein translation and localization. Recently,
dosage effects of protein translation and transport genes
are reported for plasma cell leukemia, a cancer closely
related to myeloma [31]. Overdrive of translation machines
is a feature of cancer cell proliferation [32-34]. Dosage sen-
sitivity of the genes in translation processes indicates their
expression levels are not subject to tightly controlled dos-
age compensation and are susceptible to the influence of
copy number alteration. These results support that CNA
patterns in myeloma, such as the eight characteristic tri-
somy chromosomes in about half of all myeloma patients,
are not a by-product of myeloma genomic evolution but
have functional and consequential effects that contribute
to the pathogenesis of myeloma.
We find that gene ontology groups enriched in dosage
sensitive genes are similar to those enriched in the dif-
ferential expressed genes between HMM and NHMM
subtypes (Additional file 5: Tables S1, S2 and S3), and
these two gene sets overlap significantly. Previous gene
expression studies comparing HMM and NHMM have
found similar enriched pathways. Chng et. al. reported
over-expression of ribosomal protein and protein biosyn-
thesis genes in HMM relative to NHMM [24]. Agnelli
et. al. reported that up-regulated genes in HMM com-
pared to NHMM are mainly involved in protein biosyn-
thesis, encoding for ribosomal proteins and mitochondrial
ribonucleoproteins [23], and these genes mainly mapped to
the hyperdiploid chromosomes. Therefore, distinct CNA
patterns in HMM and NHMM are likely to be the cause
for most differentially expressed genes between the two
subtypes through dosage effect.
We also identify specific dosage sensitive genes that
may play critical roles in myeloma development. For ex-
ample (Additional files 1, 2 and 3), Tamura et. al. [35]
showed that EVOLV7 could be involved in prostate cancer
growth and survival. Camps et. al. [36] identified that loss
of POLR1D function affects cell viability in colorectal can-
cers. Cell cycle role of CCNC and its effect on several can-
cer types were reported by several authors [37,38]. Steen
et. al. previously reported the role of NULP1 (TCG25) in
c e l ld e a t hc o n t r o la n dt u m o rg r o w t h[ 3 9 ] .A d d i t i o n a lf i l e4
includes literature search for the top 50 dosage sensitive
genes for both IFM and Dickens dataset.
A less studied phenomenon in integrative genomics is
dosage resistance or compensation. Essential genes whose
expression level must be tightly regulated may achieve
dosage resistance through feedback loops that compensate
for copy number changes [40]. A recent study reports that
amplified genes may be over-expressed, unchanged or
down-regulated in cervical cancer [41]. Signaling and
receptor activity functions are enriched in genes whose ex-
pression negatively correlates with copy number in glio-
blastoma [42]. In our analysis, we found apoptosis as an
enriched category in dosage resistant genes but not in dos-
age sensitive genes. The gene ontology category “apoptosis”
encompasses a large number of genes with both “signaling”
and other functions. This ontology as any categorization is
subjective and incomplete with gaps in knowledge. The
apoptosis pathway is often mutated or inhibited in cancer
cells for its tumor suppressing function [43]. Dickens et al.
have identified 170 “cell death” signature genes whose
homozygous deletions and corresponding loss of expres-
sion in myeloma are adverse to overall survival [21]. These
results point to future studies on differential dosage sensi-
tivity and resistance of pro- and anti-proliferation pathways
and their variation across patients as therapeutic targets
and prognosis markers.
There are several limitations of this study. First, we
haven’t considered indirect effects of CNAs. CNAs could
directly alter the expression level of transcription factors
and signaling transduction genes, which in turn affect their
downstream genes’ expression. Partly alleviating this limi-
tation, our identification of dosage-resistant genes may be
reflection of indirect effects. Second, parameters and
thresholds used in the analysis are chosen based on empir-
ical distributions and consideration for reducing noise,
such as computing DES only for genes with CNA fre-
quency >10% and regarding genes as dosage-sensitive at
DES> 0.4, but choosing other parameters may lead to dif-
ferent results. We have used DSE>0.3 to select dosage
sensitive genes and obtained similar enriched pathways in
dosage sensitive genes. The agreement between the two
myeloma datasets with different patient cohorts also sup-
ports the robustness of the analysis method and parame-
ters used. These limitations point to directions for further
improvement of dosage effect analysis.
Conclusions
In summary, dosage effect score is a gene-wise meas-
ure that integrates copy number alteration with gene
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http://www.biomedcentral.com/1471-2164/14/672expression in a quantitative manner. It could be an im-
portant tool to understanding the functional impact of
CNAs in tumor development. Our results indicate that
CNAs in myeloma impact the gene expression level of a
substantial number of genes. Interestingly, our analysis
suggests that even though differentially expressed genes
between HMM and NHMM are enriched in the trisomy
chromosomes, chromosomal proportion of dosage sensi-
tive genes is highest for non-trisomy chromosomes. Also,
higher expression levels associated with stronger dosage
effect. The dosage sensitive genes are enriched by protein
translation and localization processes, and dosage resistant
genes are enriched by genes with function in apoptosis.
These results support that CNAs exert functional effect in
cancer transcriptome in part through direct dosage effect
of CNA-affected genes, and therefore recurrent CNAs can
be selected during cancer clonal evolution due to their
dosage effect on specific pathways. The gene lists identi-
fied in our analysis will help identify functional targets in
myeloma. The R code is available at http://www.canevolve.
org/dosageEffect/ for applying this method to other stud-
ies profiling paired gene expression and copy number can-
cer samples.
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